Improvement seen in all signs of photoaging as early as week 4 and through 12 weeks, with no major irritation<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, April 10, 2024 (HealthDay News) — Stabilized bioactive retinol is efficacious for improving signs of photoaging, without causing major irritation, according to a study published in the April issue of the Journal of Drugs in Dermatology<\/em>.<\/p>\n Patricia Farris, M.D., from Tulane University School of Medicine in New Orleans, and colleagues examined the comprehensive efficacy and tolerability of topical 0.1 percent stabilized bioactive retinol. Six vehicle-controlled studies of 0.1 percent stabilized bioactive retinol in women with mild-to-moderate signs of photodamage were included in the analysis. A total of 237 participants received retinol and 234 received vehicle.<\/p>\n The researchers found greater improvements from baseline in all signs of photoaging for retinol versus vehicle as early as week 4 and through 12 weeks of application. Irritation was experienced by few participants; all events were transient and mild to moderate. Erythema and skin scaling\/peeling were the most common signs of irritation.<\/p>\n “At the time of this publication, our analysis represents one of the largest datasets demonstrating the clinical benefit and tolerability of retinol,” the authors write. “These pooled results demonstrate that a well-formulated topical retinol at a strength of 0.1 percent can be an effective cosmeceutical solution for individuals seeking to improve signs of photoaging.”<\/p>\n Several authors disclosed ties to pharmaceutical and dermatology companies, including Kenvue, which funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n